Article Text
Abstract
Background A recent trial failed to show any benefit of stenting plus medical therapy over medical therapy alone in patients with symptomatic intracranial stenosis. We aimed to examine whether the symptomatic qualifying artery modifies the effect of stenting plus medical therapy.
Methods This is a post-hoc analysis of the CASSISS trial that included patients with symptomatic intracranial stenosis, randomly assigned to undergo stenting plus medical therapy or medical therapy alone; 358/380 patients were included. Multivariable logistic regression analysis was used with an interaction term to estimate the altered treatment effect by the qualifying artery. The primary outcome was a composite of stroke or death within 30 days or stroke in the qualifying artery territory beyond 30 days through 1 year. The five secondary outcomes included stroke or death related to the qualifying artery territory at 2 and 3 years.
Results No significant treatment allocation-by-stenosis site interaction was observed (Pinteraction=0.435). Compared with medical therapy alone, the adjusted ORs for stenting plus medical therapy were 2.73 (95% CI 0.42 to 17.65) for internal carotid artery stenosis, 1.20 (95% CI 0.29 to 4.99) for M1 stenosis, 0.23 (95% CI 0.02 to 2.31) for vertebral artery stenosis, and 1.33 (95% CI 0.34 to 5.28) for basilar artery stenosis. Of the five secondary outcomes, none showed a significant treatment allocation-by-stenosis site interaction including stroke in the qualifying artery territory at 2 years (Pinteraction=0.659) and 3 years (Pinteraction=0.493).
Conclusions Among patients with transient ischemic attacks or ischemic stroke due to severe intracranial atherosclerotic stenosis, there was no evidence that the symptomatic qualifying artery could determine the addition of stenting to medical therapy.
- Artery
- Stenosis
- Atherosclerosis
- Angioplasty
- Stent
Data availability statement
Data are available upon reasonable request. Requests to access an anonymized dataset supporting the conclusions may be obtained following review.
Statistics from Altmetric.com
Data availability statement
Data are available upon reasonable request. Requests to access an anonymized dataset supporting the conclusions may be obtained following review.
Footnotes
QW, JW and BZ contributed equally.
Contributors QW, BZ, JQ, SX, PW, GZ, ZJ, CW, JY, HS, and YL designed the study. BZ, LJ, PG, TW, DW, TL, YH, ZZ, YC, WW, WH, HS, and YL conducted the trial and collected information. QW drafted the manuscript. JW independently contributed to the statistical analysis. HS is the guarantor for this work and accepts responsibility for the data presented. All authors critically reviewed the manuscript and approved the final version.
Funding This study was supported by grants from the National Natural Science Foundation of China (82101383), the China Postdoctoral Science Foundation project (2021MD703829), and the Key research and development projects in Heilongjiang Province (2022ZX06C03).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.